Swedish Orphan Biovitrum AB (publ) - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SWOBY Over the counter 2830 www.sobi.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Swedish Orphan Biovitrum AB (publ)

Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030 - Feb 18th, 2026 12:36 am
Sobi’s Arthrosi Deal Brings Late Stage Gout Asset Into Focus - Feb 12th, 2026 6:14 pm
Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout - Feb 9th, 2026 7:47 am
Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN - Jan 16th, 2026 4:49 am
Sobi buys Arthrosi to expand gout treatment pipeline - Dec 15th, 2025 2:26 am
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. - Dec 14th, 2025 11:06 pm